Indisulam clinical trials
Also written E7070.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 1998
How each study uses indisulam is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 1998 (2)
| Year | Studies |
|---|---|
| 1998 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 4
Eisai Inc. (3) · Eisai Limited (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · M.D. Anderson Cancer Center (1) · Eisai Co., Ltd. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses indisulam is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Dose-Finding Study of E7070 in Combination With IrinotecanCompletedPhase 1Eisai Inc.NCT00060567Written as E7070 + irinotecan combination
- E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic SyndromesCompletedPhase 2M.D. Anderson Cancer CenterNCT01692197Written as E7070
- An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With CapecitabineTerminatedPhase 2Eisai LimitedNCT00165880Written as E7070
- Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal CancerCompletedPhase 2Eisai LimitedNCT00165854Written as E7070
- A Study of E7070 in Patients With Gastric CancerTerminatedPhase 1/2Eisai Co., Ltd.NCT00165594Written as E7070
- E7070 in Treating Patients With Stage IV MelanomaCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00014625Written as indisulam
- E7070 in Treating Patients With Solid TumorsCompletedPhase 1European Organisation for Research and Treatment of Cancer - EORTCNCT00003976Written as indisulam
- E7070 in Treating Patients With Solid TumorsCompletedPhase 1European Organisation for Research and Treatment of Cancer - EORTCNCT00003981Written as indisulam
- A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell CarcinomaCompletedPhase 2Eisai Inc.NCT00059735Written as E7070
- Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer PatientsCompletedPhase 2Eisai Inc.NCT00080197Written as E7070
- An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and OxaliplatinCompletedPhase 2Eisai LimitedNCT00165867Written as E7070
Codes
What other systems call indisulam · ClinicalTrials.gg INT004399
- UNII (FDA) WJ98J3NM90INDISULAMConfirmed FDA, Wikidata
- Wikidata Q27078056indisulamConfirmed FDA, Wikidata
- NCI Thesaurus C25797IndisulamOne source FDA
- DrugBank DB06370One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WJ98J3NM90 | INDISULAM | Confirmed FDA, Wikidata |
| Wikidata | Q27078056 | indisulam | Confirmed FDA, Wikidata |
| NCI Thesaurus | C25797 | Indisulam | One source FDA |
| DrugBank | DB06370 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.